WuXi Companies See Growth After ‘Limited’ Biosecure Impact (1)

WuXi AppTec Co. and WuXi Biologics Cayman Inc. said they see a brighter 2025 for the Chinese biotech and drug companies after the US Biosecure legislation that threatened to cut them out from their biggest market failed to pass.

“Sure, Biosecure had an impact on our business,” Chris Chen, WuXi Biologics chief executive officer, said Wednesday in a presentation at the JPMorgan Healthcare Conference in San Francisco. Although the company managed to garner some 150 projects around the world in 2024, it was a relief that the bill didn’t pass, he added.

The remarks are rare public comments on ...